Neumora Therapeutics (NASDAQ:NMRA) Posts Earnings Results, Misses Expectations By $0.02 EPS

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.02), Zacks reports.

Neumora Therapeutics Trading Up 4.5%

Shares of NMRA stock traded up $0.03 during trading hours on Monday, hitting $0.69. The company's stock had a trading volume of 1,213,234 shares, compared to its average volume of 2,563,140. The business has a fifty day moving average of $0.92 and a 200-day moving average of $4.64. The stock has a market cap of $112.01 million, a price-to-earnings ratio of -0.37 and a beta of 2.96. Neumora Therapeutics has a twelve month low of $0.62 and a twelve month high of $17.19.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Royal Bank of Canada reissued a "sector perform" rating and set a $4.00 price target on shares of Neumora Therapeutics in a report on Tuesday, March 4th. Needham & Company LLC reissued a "buy" rating and set a $5.00 price target on shares of Neumora Therapeutics in a report on Thursday, April 10th. William Blair lowered shares of Neumora Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Monday, March 10th. HC Wainwright lowered their target price on shares of Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Finally, Stifel Nicolaus lowered shares of Neumora Therapeutics from a "buy" rating to a "hold" rating and lowered their target price for the stock from $6.00 to $2.00 in a research report on Friday, March 7th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $9.29.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.